Company: IXHL
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001213900-25-036057
Chunk: 23

Company: Incannex Healthcare Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 23
---
 or round up to the next whole share. Exercise Limitation.A holder will not have the right to exercise any portion of the Warrants if the holder (together with its affiliates) would beneficially own in excess of 4.99% (or, upon election by a holder prior to the issuance of any warrants, 9.99%) of the number of shares of common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Warrants. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, upon at least 61 days’ prior notice from the holder to us with respect to any increase in such percentage. Exercise Price.The exercise price of each Pre -FundedWarrant is $0.0001 per Pre -FundedWarrant Share. The Series A Warrants have an initial exercise price of $2.16 per Series A Warrant Share. These exercise prices of the Warrants and the number of shares underlying the Warrants are subject to adjustment as described below. Adjustments to Exercise Prices and Underlying Shares Recapitalization and Other Events: The exercise prices of the Warrants and number of shares underlying the Warrants are subject to adjustment for stock splits, dividends, combinations, recapitalization and similar events. Series A Warrant Adjustment at the “Release Date”: At the Adjustment Date (defined below), the exercise price of the Series A Warrants will be reduced (but in no event increased) to the greater of (I) the Floor Price (as defined below) and (II) the lowest daily dollar -volume - weighted-average -priceduring the period beginning two full trading days prior to the Release Date and ending on the 10 thtrading day after the Release Date. Upon any such resulting adjustment of the exercise price in the Series A Warrants, the number of Series A Warrant Shares issuable under the Series A Warrants will be increased such that the aggregate exercise price of a Series A Warrants (adjusted for any exercises by a holder prior to this adjustment) will remain unchanged following such adjustment. No adjustment in connection with a Release Date or otherwise may result in an adjustment of the exercise price to a price less than the Floor Price. As a result, the aggregate number of shares of common stock underlying all of the Series A Warrants, may increase from 11,574,090 to up to 115,740,900, assuming full adjustment of the exercise